Clinical trials: Embryonal Neoplasm
Melanoma
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of SHR-1701 combined with temozolomide in the treatment of advanced melanoma.
- Trial name
- NCT05106023
- Testing
- SHR-1701, Temozolomide
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Yong Chen
Breast Cancer, Germ Cell Tumor
Multidisciplinary Approach to Fatigue
Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour
- Trial name
- NCT05502224
- Testing
- Ergospirometry
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Jules Bordet Institute
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB.
- Trial name
- NCT04943848
- Testing
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial…
- Trial name
- NCT01424878
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Squamous Cell Lung Cancer
Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)
This is a multicenter, non-interventional, retrospective study (with two prospective cohorts), including previously treated patients with melanoma, squamous cell lung cancer in the late stages (inoperable or metastatic) and…
- Conditions
- Melanoma, Squamous Cell Lung Cancer, Uveal Melanoma, Hodgkin Lymphoma
- Trial name
- ICIPRESIST19 (NCT04025424)
- Testing
- Genetic tests of the available tumor and plasma samples
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- Russian Academy of Medical Sciences
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Brain and Central Nervous System Tumors
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006358
- Testing
- temozolomide, thalidomide
- Where
- 11 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or…
- Trial name
- NCT03457948
- Testing
- Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nicholas Fidelman, MD
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Malignant Gliomas
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
- Trial name
- NCT01670890
- Testing
- TMZ, TMZ plus CDDP
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Glioblastoma Multiforme
A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research
Clinical research can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
- Trial name
- NCT05958485
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Craniopharyngioma, Apoplexy
Craniopharyngioma With Tumoral Hemorrhage
Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected.
- Trial name
- NCT04937335
- Testing
- intratumoral hemorrhage
- Volunteers
- 185 people
- Sponsor
- Tongji Hospital
Respiratory Tract Neoplasms, Thymic Neoplasms
High Dose Somatostatin Analogues in Neuroendocrine Tumors
Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg.
- Conditions
- Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms, Gastrointestinal Neoplasms
- Trial name
- HIDONET (NCT00990535)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Federico II University
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Melanoma
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV, or relapsed…
- Trial name
- NCT00005617
- Testing
- dendritic cell-MART-1 peptide vaccine, leukapheresis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Non Hodgkin Lymphoma, Non Small Cell Lung Cancer
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
The explosion of novel therapies targeting tumor mutations or immune molecules requests to define or better characterize the mutational profiles of tumors that are none or insufficiently explored so far.
- Conditions
- Non Hodgkin Lymphoma, Non Small Cell Lung Cancer, Glioma
- Trial name
- IDeATIon (NCT03706625)
- Where
- France
- Volunteers
- 201 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma, BRAF V600 Mutation
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05810740
- Testing
- Binimetinib 15 MG, Binimetinib 45 MG
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Lung Neoplasm, Lymphoma
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
To determine the minimum scan duration for fluorine-18 positron-emitting radioactive isotope-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans performed on a total-body PET/CT scanner…
- Conditions
- Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose
- Trial name
- NCT04478318
- Testing
- uEXPLORER/mCT, mCT/uEXPLORER
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.